These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 8294874)

  • 1. The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.
    Glas R; Ohlén C; Höglund P; Kärre K
    J Exp Med; 1994 Feb; 179(2):661-72. PubMed ID: 8294874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes.
    Glas R; Franksson L; Ohlén C; Höglund P; Koller B; Ljunggren HG; Kärre K
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11381-5. PubMed ID: 1454824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
    Jhaver KG; Rao TD; Frey AB; Vukmanović S
    J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.
    Apasov S; Sitkovsky M
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2837-41. PubMed ID: 8464897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.
    Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Ploegh HL
    Eur J Immunol; 1995 Jan; 25(1):174-8. PubMed ID: 7843229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allospecific cytotoxic T cells generated from beta 2m-/- mice in primary MLC: analysis of activation requirements, specificity, and phenotype.
    Lamousé-Smith E; McCarthy SA
    Cell Immunol; 1997 Aug; 179(2):107-15. PubMed ID: 9268494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
    Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
    Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
    Zügel U; Schoel B; Kaufmann SH
    J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I phenotype and function of human beta 2-microglobulin transgenic murine lymphocytes.
    Bjerager L; Pedersen LO; Bregenholt S; Nissen MH; Claesson MH
    Scand J Immunol; 1996 Dec; 44(6):615-22. PubMed ID: 8972744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice.
    Cook JR; Solheim JC; Connolly JM; Hansen TH
    J Immunol; 1995 Jan; 154(1):47-57. PubMed ID: 7995959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
    Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
    J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ and CD8+ alpha beta, and gamma delta T cells are cytotoxic effector cells of beta 2-microglobulin-deficient mice against cells having normal MHC class I expression.
    Udaka K; Marusić-Galesić S; Walden P
    J Immunol; 1994 Sep; 153(6):2843-50. PubMed ID: 7915743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class I heavy chain-dependent expression of discontinuous antigenic epitopes on beta 2-microglobulinb is inducible with peptide-ligand.
    Tatake RJ; Trymbulak WP; Zeff RA
    Transplantation; 1995 Jan; 59(1):124-30. PubMed ID: 7530867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha beta TCR+ cells are a minimal fraction of peripheral CD8+ pool in MHC class I-deficient mice.
    Nesić D; Santori FR; Vukmanović S
    J Immunol; 2000 Aug; 165(4):1896-901. PubMed ID: 10925270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LCMV-specific, class II-restricted cytotoxic T cells in beta 2-microglobulin-deficient mice.
    Muller D; Koller BH; Whitton JL; LaPan KE; Brigman KK; Frelinger JA
    Science; 1992 Mar; 255(5051):1576-8. PubMed ID: 1347959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of thymus-independent intestinal intraepithelial lymphocytes by beta 2-microglobulin.
    Neuhaus O; Emoto M; Blum C; Yamamoto S; Kaufmann SH
    Eur J Immunol; 1995 Aug; 25(8):2332-9. PubMed ID: 7664795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II molecules bind indiscriminately self and non-self peptide homologs: effect on the immunogenicity of non-self peptides.
    Sette A; Sidney J; Gaeta FC; Appella E; Colón SM; del Guercio MF; Guéry JC; Adorini L
    Int Immunol; 1993 Jun; 5(6):631-8. PubMed ID: 8347557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
    Uger RA; Barber BH
    J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.